| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713999 | XSPIRE PHARMA | Thrombin receptor antagonists |
May, 2024
(8 months from now) | |
| US7304078 | XSPIRE PHARMA | Thrombin receptor antagonists |
Dec, 2027
(4 years from now) | |
Zontivity is owned by Xspire Pharma.
Zontivity contains Vorapaxar Sulfate.
Zontivity has a total of 2 drug patents out of which 0 drug patents have expired.
Zontivity was authorised for market use on 08 May, 2014.
Zontivity is available in tablet;oral dosage forms.
Zontivity can be used as reduction of thrombotic cardiovascular events, reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad).
The generics of Zontivity are possible to be released after 23 December, 2027.
Drugs and Companies using VORAPAXAR SULFATE ingredient
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
ZONTIVITY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic